Indiatimes15d
Biocon shares in focus after successful results of Yesintek in Phase 3
Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the last six months, it has decreased by 10.84%, while the stock fell by 12.23% ...
cnbctv1818d
Biocon Biologics’ biosimilar Yesintek shows positive phase 3 results for psoriasis treatment
Biotechnology firm Biocon Ltd on Friday (March 7) said its subsidiary Biocon Biologics Ltd has announced positive results from its phase 3 clinical trial for Yesintek, a biosimilar to ustekinumab ...
Yahoo Finance18d
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
BRIDGEWATER, N.J., and BENGALURU, India, March 7, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code ...
BioSpace19d
Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States
BRIDGEWATER, N.J. and PETERSBURG, Va. and BENGALURU, India, March 6, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company ...
Morningstar20d
Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States
BRIDGEWATER, N.J. and PETERSBURG, Va. and BENGALURU, India, March 6, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd ...
The Victoria Advocate20d
Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States
Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan.It has a pipeline of 12 biosimilar assets under ...
Longview News-Journal20d
Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to ...
Equity Bulls20d
AXISCADES' subsidiary Mistral and Altera Forge Strategic Alliance
Mistral Solutions Private Ltd, (Mistral) a subsidiary of AXISCADES Technologies Limited (AXISCADES), a chip to product company and a pioneer in Defense, Electronics, Semiconductor and Artificial ...
India Infoline25d
Biocon launches generic Liraglutide in the UK
Biocon Limited announced on Friday that it has launched its Glucagon Glucagon-like Peptide-1 (GLP-1) analog, Liraglutide, in the United Kingdom (U.K.). The drug is recommended for treatment of ...
pharmaphorum28d
Biocon buys Viatris biosimilars for $3.3bn, eyes IPO
India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...
Daily28d
Biocon Biologics unveils Yesintek biosimilar to Stelara in US
Bengaluru: BioconBiologics Ltd, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., has announced that YESINTEK (ustekinumab-kfce) is now available to patients in the United ...